Novel candidates emerging from Genevive’s discovery platform.
Genevive’s discovery platform has produced a robust preclinical pipeline of microbiome-inspired candidates. Lead program GTx-455 promotes mucosal healing in inflammatory bowel disease. Additional patented programs target metabolic disease by enhancing barrier function and insulin sensitivity, while mucosal immunity candidates address inflammation, autoimmunity, and oncology.
A neuromodulation program for autism spectrum disorder has been out-licensed to Stanford University and University of Oregon, highlighting the platform’s broad potential to deliver precise therapies across major unmet medical needs.
Microorganisms regulate health and disease.
We now have the capability to interrogate these processes, both ‘the good’ and ‘the bad,’ at a pathway and molecular level.
Genevive’s discovery platform has produced a robust preclinical pipeline.
We have built the technology to mine the genomes of living organisms.
Data science and differential analysis to uncover novel compounds from nature.
Synthetic biology with contextual and functional high-throughput screening turns these discoveries into products across broad applications.
Genevive’s discovery platform is a disease agnostic approach to identify novel peptides and metabolites from the microbial world.
